biotickrCorline Biomedical AB
The CLBIO-SS stock trades on Nasdaq Stockholm Ab
Company Description
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to improve kidney transplantation, cell therapies, and applications in the evolving field of regnerative medicine. The Company also provides surface coatings, making medical device implants blood, and biocompatible. Corline Biomedical operates in Sweden.
Technology
CHC™ Technology
The CHC™, Corline Heparin Conjugate, is based on pre-assembled aggregates of heparin molecules. The conjugate is used as a stand-alone pharmaceutical compound, the case of Renaparin®, or as part of a larger complex, for example Cytoparin™.
The inner lining of a blood vessel wall is the only known fully blood compatible surface. But by mimicking nature itself, Corline's CHC™ technology comes a close second.
The CHC™, Corline Heparin Conjugate, is based on pre-assembled aggregates of heparin molecules. The conjugate is used as a stand-alone pharmaceutical compound, the case of Renaparin®, or as part of a larger complex, for example Cytoparin™.
The inner lining of a blood vessel wall is the only known fully blood compatible surface. But by mimicking nature itself, Corline's CHC™ technology comes a close second.
Drug Pipeline
Source: Corline Biomedical AB - 20221109
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
Cytoparin
Diabetes Type 1
Reg/Com
Renaparin
Kidney Transplantation
Reg/Com
0 Comments on CLBIO-SS stock
Newest
Conversation